Navigation Links
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Date:5/30/2009

Group (NCIC CTG) based at Queen's University in Kingston, Ontario. The trial was further supported by an unrestricted grant from Sanofi-Aventis.

Webcast and Conference Call Today

OncoGenex will hold a live webcast and conference call of presentations made at a Company hosted reception during the 2009 American Society of Clinical Oncology Annual Meeting (ASCO) today, May 30, 2009. The webcast will begin at 7:10 p.m. EDT.

During the reception, OncoGenex management and guest speakers will provide a comprehensive review of the final results of the randomized Phase 2 trial presented at the ASCO Annual Meeting, as well as discuss the treatment landscape and the relevance of clinical trial endpoints for prostate cancer.

To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-627-6544 (U.S. & Canada) or 719-325-4857 (International). A webcast replay will be available approximately two hours after the call and will be archived at www.oncogenex.com.

About OGX-011

OGX-011 is designed to inhibit the production of clusterin, a protein that is associated with cancer treatment resistance and is currently being evaluated in Phase 2 clinical trials in prostate, lung and breast cancer. At the 2009 American Urological Association Annual Meeting, OncoGenex reported Phase 2 data with OGX-011 in combination with second-line treatment of metastatic castrate resistant prostate cancer showing better than expected survival results, reductions in levels of clusterin, durable reductions in pain, and a decline in PSA, a protein that is often elevated in patients with prostate cancer.

Based on clinical results to date, OncoGenex intends to conduct Phase 3 registration trials
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
2. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
3. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
4. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
7. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
9. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 SoundConnect’s ... to introduce cutting edge communication technology, provide continued ... upgrades. This webinar series demonstrates online communication features ... leverage web conferencing’s most innovative and powerful tools. ...
(Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ...
(Date:12/24/2014)... 2014 Nashville Fertility Center announced that ... American Society for Reproductive Medicine (ASRM), a leading professional organization ... In his new role as treasurer, Dr. Hill also fills ... voice in furthering the mission of ASRM. , Dr. ...
(Date:12/24/2014)... San Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab pictures for ... lab mates. , For those struggling to think of a ... in the Lab Contest provides the ideal holiday presents. The ...
Breaking Biology Technology:SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
... -- Shandong Zhouyuan Seed,and Nursery Co., Ltd. (OTC ... incorporated in the State of Delaware, announced,that its ... and,Nursery Co., Ltd. ("Zhouyuan" or "the Company"), had ... Kun Yuan Seeds Co., Ltd. ("Kun Yuan") on,August ...
... 2007, SAN DIEGO, Sept. 17 Neurocrine ... Neurocrine Biosciences will,present at the A.G. Edwards Annual ... September 19, 2007 at 1:30 p.m. Eastern,Time (ET) ... be,simultaneously webcast and may be accessed on the ...
... Conn., Sept. 17 Diageo (NYSE: DEO ),the ... to announce,its sponsorship of a physician,s training program in ... of the State of,New York (MSSNY). The program, ... developed to better prepare physicians to address and assess ...
Cached Biology Technology:Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company 2Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company 3Diageo Sponsors Medical Society of the State of New York's Physicians Training Program 2Diageo Sponsors Medical Society of the State of New York's Physicians Training Program 3
(Date:1/22/2015)... Jan. 16, 2015  A man-made form of insulin delivered ... mental capabilities in adults with mild cognitive impairment and ... by researchers at Wake Forest Baptist Medical Center. ... amnesic mild cognitive impairment (MCI) or mild to moderate ...
(Date:1/22/2015)... Jan. 21, 2015  Analyst Report Issued by Small Cap IR. ... showed that planet-wide, transactions at merchants on the leading payment ... number of credit, debit, and prepaid cards reached 6.54 billion.  ... of fraudulent card usage in 2012, and credit and debit ...
(Date:1/22/2015)... Inc. , a market leader of iris-based identity authentication solutions, ... the new role of Senior Vice President of Mobile and ... platforms and wearable solutions for EyeLock,s technologies. Gerber brings more ... industry to his role at EyeLock, with expertise in human ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... ORLANDO, Fla. The American Association for Cancer Research ... Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and ... Beverly Sackler AACR Fellowships for Ileal Carcinoid Tumor Research. ... the Caring for Carcinoid Foundation (CFCF) and the Raymond ...
... at Marshall University is conducting research that may someday lead ... Dr. Elmer M. Price, who heads the research team ... his group has identified and analyzed unique adult animal stem ... neurons they found appear to have many of the qualities ...
... A prototype scanner aboard the international space station has been ... months since it was launched, providing scientists with a new ... from oil spills to plankton blooms. The images and ... world through an online clearinghouse coordinated by Oregon State University. ...
Cached Biology News:Scientists awarded carcinoid tumor and pancreatic neuroendocrine tumor research grants 2Scientists awarded carcinoid tumor and pancreatic neuroendocrine tumor research grants 3Data streaming in from Space Station to OSU lab 2Data streaming in from Space Station to OSU lab 3
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
... RNAi Kit is optimized for ... amounts of ready-to-use dsRNA for ... The MEGAscript RNAi Kit is ... transcription technol-ogy and includes reagents ...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... Using its actuators as building ... customized work cell-level ,robotic solutions that ... applications. Beyond the base ,system, Parker ... vacuum cups, custom structures, and ,guarding., ...
Biology Products: